Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study

Rosso, Aldana LU ; Juliusson, Gunnar LU ; Lorenz, Fryderyk ; Lehmann, Sören ; Derolf, Åsa ; Deneberg, Stefan ; Jädersten, Martin ; Antunovic, Petar ; Cammenga, Jörg LU and Möllgård, Lars , et al. (2021) In Leukemia & Lymphoma 62(8). p.1973-1981
Abstract

The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-2019. Of 327 patients with AML (non-APL) with MRD-results reported in complete remission after two courses of intensive chemotherapy 229 were MRD-negative (70%), as defined by <0.1% cells with leukemia-associated immunophenotype in the bone marrow. MRD-results were reported to clinicians in real time. Multivariate statistical analysis adjusted for known established risk factors did not indicate an association between MFC-MRD and overall... (More)

The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-2019. Of 327 patients with AML (non-APL) with MRD-results reported in complete remission after two courses of intensive chemotherapy 229 were MRD-negative (70%), as defined by <0.1% cells with leukemia-associated immunophenotype in the bone marrow. MRD-results were reported to clinicians in real time. Multivariate statistical analysis adjusted for known established risk factors did not indicate an association between MFC-MRD and overall survival (HR: 1.00 [95% CI 0.61, 1.63]) with a median follow-up of 2.7 years. Knowledge of the importance of MRD status by clinicians and individualized decisions could have ameliorated the effects of MRD as an independent prognostic factor of overall survival.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia & Lymphoma
volume
62
issue
8
pages
1973 - 1981
publisher
Taylor & Francis
external identifiers
  • pmid:33719843
  • scopus:85102415240
ISSN
1029-2403
DOI
10.1080/10428194.2021.1889539
language
English
LU publication?
yes
id
0e098711-d3f9-4153-84a1-f5c665b16a9a
date added to LUP
2021-03-21 07:01:59
date last changed
2024-06-13 09:07:03
@article{0e098711-d3f9-4153-84a1-f5c665b16a9a,
  abstract     = {{<p>The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-2019. Of 327 patients with AML (non-APL) with MRD-results reported in complete remission after two courses of intensive chemotherapy 229 were MRD-negative (70%), as defined by &lt;0.1% cells with leukemia-associated immunophenotype in the bone marrow. MRD-results were reported to clinicians in real time. Multivariate statistical analysis adjusted for known established risk factors did not indicate an association between MFC-MRD and overall survival (HR: 1.00 [95% CI 0.61, 1.63]) with a median follow-up of 2.7 years. Knowledge of the importance of MRD status by clinicians and individualized decisions could have ameliorated the effects of MRD as an independent prognostic factor of overall survival.</p>}},
  author       = {{Rosso, Aldana and Juliusson, Gunnar and Lorenz, Fryderyk and Lehmann, Sören and Derolf, Åsa and Deneberg, Stefan and Jädersten, Martin and Antunovic, Petar and Cammenga, Jörg and Möllgård, Lars and Wennström, Lovisa and Ölander, Emma and Ehinger, Mats and Fogelstrand, Linda and Höglund, Martin and Lazarevic, Vladimir Lj}},
  issn         = {{1029-2403}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{8}},
  pages        = {{1973--1981}},
  publisher    = {{Taylor & Francis}},
  series       = {{Leukemia & Lymphoma}},
  title        = {{Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study}},
  url          = {{http://dx.doi.org/10.1080/10428194.2021.1889539}},
  doi          = {{10.1080/10428194.2021.1889539}},
  volume       = {{62}},
  year         = {{2021}},
}